163 related articles for article (PubMed ID: 20926858)
1. Biweekly vinorelbine and gemcitabine as second-line treatment and beyond in non-small cell lung cancer.
Chelis L; Xenidis N; Amarantidis K; Prassopoulos P; Chamalidou E; Neanidis K; Mikroulis D; Chatzaki E; Karakitsos P; Kakolyris S
Chemotherapy; 2010; 56(5):353-8. PubMed ID: 20926858
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial.
Hainsworth JD; Burris HA; Litchy S; Erland JB; Hon JK; Brierre JE; Greco FA
Cancer; 2000 Mar; 88(6):1353-8. PubMed ID: 10717616
[TBL] [Abstract][Full Text] [Related]
4. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
Herbst RS; Khuri FR; Lu C; Liu DD; Fossella FV; Glisson BS; Pisters KM; Shin DM; Papadimitrakopoulou VA; Kurie JM; Blumenschein G; Kies MS; Zinner R; Jung MS; Lu R; Lee JJ; Munden RF; Hong WK; Lee JS
Cancer; 2002 Jul; 95(2):340-53. PubMed ID: 12124835
[TBL] [Abstract][Full Text] [Related]
5. Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer.
Xenidis N; Neanidis K; Amarantidis K; Dimopoulos P; Chamalidou E; Pitsiava D; Tentes A; Chatzaki E; Karakitsos P; Kakolyris S
Cancer Chemother Pharmacol; 2011 Jan; 67(1):69-73. PubMed ID: 20221602
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer.
Isokangas OP; Knuuttila A; Halme M; Mäntylä M; Lindström I; Nikkanen V; Viren M; Joensuu H; Mattson K
Ann Oncol; 1999 Sep; 10(9):1059-63. PubMed ID: 10572603
[TBL] [Abstract][Full Text] [Related]
7. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
Martoni A; Marino A; Sperandi F; Giaquinta S; Di Fabio F; Melotti B; Guaraldi M; Palomba G; Preti P; Petralia A; Artioli F; Picece V; Farris A; Mantovani L
Eur J Cancer; 2005 Jan; 41(1):81-92. PubMed ID: 15617993
[TBL] [Abstract][Full Text] [Related]
8. Biweekly triplet chemotherapy with gemcitabine, cisplatin and vinorelbine for advanced chemotherapy naïve non-small cell lung cancer.
Keskin S; Tas F; Ekenel M; Kilic L; Sen F; Yildiz I; Karabulut S; Ciftci R; Vatansever S
Tumori; 2013; 99(4):463-8. PubMed ID: 24326833
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
Hosoe S; Komuta K; Shibata K; Harada H; Iwamoto Y; Ohsaki Y; Morioka T; Origasa H; Fukushima M; Furuse K; Kawahara M
Br J Cancer; 2003 Feb; 88(3):342-7. PubMed ID: 12569374
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group.
Feliu J; López Gómez L; Madroñal C; Espinosa E; Espinosa J; Girón CG; Martínez B; Castro J; De la Gándara I; Barón MG
Cancer; 1999 Oct; 86(8):1463-9. PubMed ID: 10526274
[TBL] [Abstract][Full Text] [Related]
11. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
[TBL] [Abstract][Full Text] [Related]
12. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.
Kosmas C; Tsavaris N; Panopoulos C; Vadiaka M; Stavroyianni N; Kourelis T; Malamos N; Antonopoulos M; Kalofonos HP
Eur J Cancer; 2001 May; 37(8):972-8. PubMed ID: 11334721
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter.
Juergens R; Brahmer J; Ettinger D
Cancer Chemother Pharmacol; 2007 Apr; 59(5):621-9. PubMed ID: 16937106
[TBL] [Abstract][Full Text] [Related]
15. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of gemcitabine and vinorelbine plus cisplatin in non-small cell lung cancer.
Esteban E; Fra J; Sala M; Carrasco J; Corral N; Vieitez JM; Estrada E; Palacio I; Buesa JM; Lacave AJ
Invest New Drugs; 2002 Aug; 20(3):317-26. PubMed ID: 12201494
[TBL] [Abstract][Full Text] [Related]
17. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).
Kotsakis A; Kentepozidis N; Emmanouilidis Ch; Polyzos A; Agelidou A; Vaslamatzis M; Chandrinos V; Agelaki S; Vamvakas L; Kalbakis K; Katsaounis P; Stoltidis D; Nintos G; Hatzidaki D; Vetsika EK; Mavroudis D; Georgoulias V
Lung Cancer; 2015 Apr; 88(1):57-62. PubMed ID: 25662596
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: a phase II trial.
Laack E; Mende T; Dürk H; Kneba M; Dickgreber N; Welte T; Müller T; Scholtze J; Graeven U; Jasiewicz Y; Edler L; Hossfeld DK
Eur J Cancer; 2002 Mar; 38(5):654-60. PubMed ID: 11916547
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.
Han JY; Lee DH; Song JE; Lee SY; Kim HY; Kim HT; Lee JS
Cancer; 2008 Jul; 113(2):388-95. PubMed ID: 18484595
[TBL] [Abstract][Full Text] [Related]
20. Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study.
Petrioli R; Francini E; Fiaschi AI; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Bianco V; Roviello G
Med Oncol; 2015 Apr; 32(4):134. PubMed ID: 25796503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
